FTSE 100 today: The index and GBP slide; Ocado plunges
Investing.com - TD Cowen has reiterated its Buy rating on Rapport Therapeutics (NASDAQ:RAPP), a $524 million market cap biotech company, following strong clinical trial results for the company’s RAP-219 therapy. Despite a recent 18% weekly decline, analysts maintain a Strong Buy consensus on the stock, according to InvestingPro data.
The firm cited RAP-219’s performance in Phase II FOS data, where the treatment exceeded expectations by achieving its primary endpoint with 85% of patients experiencing a reduction of 30% or more in seizure-like events. This surpassed the success threshold of greater than 40% response rate previously established by the company and key opinion leaders.
Safety data for RAP-219 was also highlighted as strong, with no reports of aggression and a low discontinuation rate among trial participants, addressing important concerns for anti-seizure medications.
The treatment demonstrated a 78% reduction in clinical seizures and achieved a 24% seizure freedom rate in a refractory patient population, positioning RAP-219 as a potentially significant addition to existing treatment options.
TD Cowen maintained Rapport Therapeutics as a "top pick" in its coverage universe based on these clinical results. Analyst targets range from $28 to $42 per share, with InvestingPro offering additional insights through its comprehensive financial analysis and 8 more exclusive ProTips.
In other recent news, Rapport Therapeutics has announced positive topline results from its Phase 2a clinical trial of RAP-219 in patients with focal onset seizures. The trial met its primary endpoint with a 71% median reduction in long episodes, a key biomarker for seizure activity, and a 77.8% reduction in clinical seizures compared to baseline. Notably, 24% of participants achieved complete seizure freedom during the 8-week treatment period. JMP Securities and Citizens JMP have both reiterated their Market Outperform ratings on Rapport Therapeutics, maintaining a price target of $28. These firms have expressed confidence in the potential positive outcomes of the RAP-219 trial results. Rapport Therapeutics plans to report these results during a conference call and webcast scheduled for September 8, 2025. The company focuses on developing precision medicines for neurological and psychiatric disorders, and the recent trial outcomes are significant for its drug-resistant epilepsy treatment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.